Ninlaro (ixazomib) / Takeda  >>  Phase 2
Welcome,         Profile    Billing    Logout  

110 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ninlaro (ixazomib) / Takeda
NCT01660997: MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma

Withdrawn
2
0
NA
MLN9708, Dexamethasone
National Cancer Institute (NCI)
Multiple Myeloma
03/14
03/14
NCT02030405: Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Terminated
2
4
US
Ixazomib, Ninlaro, MLN9708, proteasome inhibitor
Steven E. Coutre, National Cancer Institute (NCI)
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia
11/15
11/15
2013-003266-14: Ixazomib citrate-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib citrate or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; a randomized phase II trial Inductiebehandeling met ixazomib citraat, thalidomide en lage dosis dexamethason gevolgd door onderhoudsbehandeling met ixazomib citraat of placebo bij niet eerder behandelde patiënten met Multipel Myeloom, die niet in aanmerking komen voor autologe stamceltransplantatie. Een gerandomiseerde fase II studie.

Ongoing
2
71
Europe
Ixazomib citrate (4 mg), Ixazomib citrate (3mg), Ixazomib citrate (2.3 mg),
HOVON Foundation, Dutch Cancer Society,
Multiple Myeloma
 
 
2014-002749-23: Ixazomib in combination to thalidomide - dexamethasone for patients with relapsed and/or refractory multiple myeloma

Ongoing
2
45
Europe
Thalidomide, Dexamethasone, ixazomib, Thalidomide, MLN9708,
AGMT gGmbH, Millennium Pharmaceuticals Inc.
refractory and/or relapsed multiple myeloma
 
 
2014-003467-37: Evaluation of Ixazomib, Lenalidomide, Dexamethasone in Newly Diagnosed Multiple Myeloma Patients eligible for High Dose Therapy Evaluation de l’association Ixazomib, Lenalidomide, Dexamethasone chez des patients d’âge ≤65 ans atteints de Myélome Multiple de novo et éligibles pour un traitement haute dose

Ongoing
2
46
Europe
Ixazomib, Dexamethasone, Capsule, hard, Capsule, Tablet, Revlimid 25 mg (Lenalidomide), Revlimid 5 mg (Lenalidomide), Dexamethasone
CHU de Toulouse, MILLENNIUM, CELGENE
Multiple Myeloma newly diagnosed Myelome Multiple de novo, Myeloma Myelome, Diseases [C] - Cancer [C04]
 
 
NCT01939899 / 2013-002302-32: Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma

Completed
2
29
Europe, Canada, US
IXAZOMIB, MLN9708
Millennium Pharmaceuticals, Inc.
Follicular Lymphoma
06/16
03/17
2015-004863-35: A study of ixazomib plus lenalidomide plus dexamethasone (IRd) for newly diagnosed transplant-eligible myeloma patients Myelooman ensilinjan hoitotutkimus, iksatsomibi + lenalidomid +deksametasoni (IRd) kantasolusiirtoon soveltuville uusille potilaille

Ongoing
2
120
Europe
ixazomib citrate (4mg), ixazomib citrate (3 mg), ixazomib citrate (2.3 mg), MLN9708, Capsule, Capsule, hard, NINLARO, Revlimid
Hospital District of Helsinki and Uusimaa/Helsinki University Hospital HUS, Helsinki University Hospital Comprehensive Cancer Center Hematology, Celgene, Takeda
Multiple myeloma newly diagnosed transplant-eligible patients Multippeliin myeloomaan sairastuneet potilaat, jotka soveltuvat kantasolusiirtohoitoon, Multiple myeloma Multippeli myelooma, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT02158975: Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas

Completed
2
13
US
MLN9708
University of Michigan Rogel Cancer Center
Lymphoma, T-Cell
10/16
11/16
2014-001757-16: Pomalidomide, ixazomib, and dexamethasone (PId) with or without intensification by cyclophosphamide (PICd): A phase II study in relapsed or refractory multiple myeloma

Not yet recruiting
2
60
Europe
Ixazomib, Dexamethasone, Cyclophosphamide, Ixazomib, Dexamethasone, Cyclophosphamide, Capsule, hard, Tablet, Imnovid, NINLARO®
GWT-TUD GmbH, Celgene International, Millenium Pharmaceuticals Inc.
Relapsed/refractory multiple myeloma, Relapsed/refractory multiple myeloma, Diseases [C] - Cancer [C04]
 
 
NCT02578121: UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination

Withdrawn
2
0
US
Ixazomib, Pomalidomide, Dexamethasone
University of Arkansas
Multiple Myeloma
01/17
01/17
NCT02302846: Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission

Terminated
2
5
US
Ixazomib, MLN9708
M.D. Anderson Cancer Center, Millennium: The Takeda Oncology Company
Leukemia
05/17
05/17
2016-002600-90: Treatment of unfit and frail newly diagnosed multiple myeloma patients with ixazomib, daratumumab and low dose dexamethasone (IDd) followed by ixazomib and daratumumab maintenance therapy until progression for a maximum of 2 years in . How effective is this treatment and how well is it tolerated? Behandeling van kwetsbare of niet fitte patiënten met nieuw gediagnostiseerd Multipel Myeloom met ixazomib, daratumumab en lage dosis dexamethason, gevolgd door een onderhoudsbehandeling met ixazomib en daratumumab voor maximaal 2 jaar. Wat is het effect van deze behandeling op de ziekte en wordt de behandeling goed verdragen?

Ongoing
2
132
Europe
Ixazomib citrate, daratumumab, Capsule, Concentrate for solution for infusion, Ninlaro 4 mg, DARZALEX, Ninlaro 3 mg, Ninlaro 2.3 mg
HOVON Foundation, Dutch Cancer Society, Janssen, Takeda Oncology
Multiple Myeloma, Multiple myeloma, Diseases [C] - Cancer [C04]
 
 
NCT02513498: Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease

Completed
2
50
US
Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Fred Hutchinson Cancer Center, National Cancer Institute (NCI)
Chronic Graft Versus Host Disease
01/18
06/18
UARK 2014-14, NCT02499081: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment

Completed
2
20
US
Ixazomib, (MLN 9708)
University of Arkansas, Millennium Pharmaceuticals, Inc.
Multiple Myeloma
05/18
05/18
NCT02046070 / 2013-003113-17: Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma

Completed
2
148
Europe, US, RoW
Cyclophosphamide, Ixazomib, MLN9708, Dexamethasone
Millennium Pharmaceuticals, Inc.
Multiple Myeloma
06/18
06/18
ACTRN12616000894493: A prospective, multi-centre, single arm, phase 2 assessment of the efficacy and safety of the combination of ixazomib, thalidomide and dexamethasone (ITD) for relapsed and/or refractory multiple myeloma after 1 to 3 prior lines of therapy.

Completed
2
45
 
Professor Andrew Spencer, Takeda Oncology
Multiple Myeloma
 
 
IFM2014-03, NCT02897830: Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma

Terminated
2
46
Europe
Ixazomib, MLN 9708, Lenalidomide, Revlimid, Dexamethasone
University Hospital, Toulouse, Takeda, Celgene
Multiple Myeloma
11/18
08/20
NCT02168101: Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma

Completed
2
9
US
MLN9708, ixazomib
SCRI Development Innovations, LLC, Millennium Pharmaceuticals, Inc.
Multiple Myeloma
02/19
02/19
NCT01936532: Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)

Completed
2
42
Europe
MLN9708, Lenalidomide, Dexamethasone
Nantes University Hospital
Newly Diagnosed Multiple Myeloma
03/19
06/20
NCT02410694: Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Completed
2
90
Europe, RoW
Ixazomib, Thalidomide, Dexamethasone
Arbeitsgemeinschaft medikamentoese Tumortherapie
Multiple Myeloma
03/19
05/19
NCT02412228: Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma

Active, not recruiting
2
12
US
Ixazomib, MLN978, Cyclophosphamide, cytophosphane, Dexamethasone, Ozurdex
John L. Reagan, Rhode Island Hospital, The Miriam Hospital, Memorial Hospital of Rhode Island
Multiple Myeloma
03/19
09/24
2018-003258-25: Bone StudyBone healing during Ninlaro treatment.

Not yet recruiting
2
30
Europe
Ninlaro, EMEA/H/C/003844, Capsule, Ninlaro
Odense University Hospital, Odense University Hospital
multiple myeloma Myelomatose, multiple myeloma, Diseases [C] - Cancer [C04]
 
 
NCT02917941: A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma

Completed
2
34
Japan
Ixazomib, Lenalidomide, Dexamethasone
Takeda
Relapsed and/or Refractory Multiple Myeloma
08/19
08/19
NCT02400437: Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia

Completed
2
26
US
Ixazomib, MLN9708, Dexamethasone, Decadron, Dexasone,, Diodex, Hexadrol, Maxidex, Rituximab, Rituxan
Dana-Farber Cancer Institute, Millennium Pharmaceuticals, Inc.
Waldenstrom's Macroglobulinemia
11/19
11/19
NCT03506360: Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Completed
2
13
US
Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Mayo Clinic, National Cancer Institute (NCI)
Recurrent Plasma Cell Myeloma
11/19
12/20
NCT02253316: Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

Active, not recruiting
2
236
US
Ixazomib, [14C]-ixazomib, [14C]-MLN9708, Lenalidomide, Revlimid, Dexamethasone, Aeroseb-Dex, Alba-Dex, Decaderm, Decadrol, Decadron, Decasone R.p., Decaspray, Deenar, Deronil, Dex-4, Dexace, Dexameth, Dezone, Gammacorten, Hexadrol, Maxidex, Sk-Dexamethasone
Washington University School of Medicine, Millennium Pharmaceuticals, Inc., Multiple Myeloma Research Consortium
Multiple Myeloma
02/20
08/24
2013-001443-31: Phase II trial studying the efficacy of a triplet combination of MLN9708, lenalidomide and dexamethasone as induction prior to, and as consolidation after high-dose therapy with peripheral stem cell transplantation followed by MLN9708 maintenance in the initial management of multiple myeloma in patients younger than 66 years.

Not yet recruiting
2
42
Europe
MLN9708, Revlimid, DEXAMETHASONE, Capsule, Tablet, REVLIMID
CHU de Nantes, Millennium
Young untreated patients with multiple myeloma, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT02169791: Nonmyeloablative Haploidentical Transplant Followed by MLN9708

Completed
2
29
US
MLN9708
Northside Hospital, Inc., Millennium Pharmaceuticals, Inc.
Acute Leukemia, Chronic Leukemia, Myelodysplastic Syndrome, Lymphomas, Multiple Myeloma
07/20
07/20
C16029, NCT03170882 / 2016-004742-28: A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma

Completed
2
122
Europe, Canada, US, RoW
Ixazomib, NINLARO, MLN9708, Pomalidomide, Dexamethasone
Millennium Pharmaceuticals, Inc.
Relapsed and/or Refractory Multiple Myeloma
08/20
11/21
BMT CTN 1302, NCT02440464: Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma

Completed
2
57
US
Allogeneic HSCT, Allogeneic hematopoietic stem cell transplant, Fludarabine, Fludara, Melphalan, Alkeran, Bortezomib, Velcade®, Ixazomib, MLN9708, Ninlaro, Placebo, sugar pill
National Heart, Lung, and Blood Institute (NHLBI), Blood and Marrow Transplant Clinical Trials Network, National Cancer Institute (NCI), National Marrow Donor Program
Multiple Myeloma
10/20
10/20
NCT02547662: Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia

Completed
2
17
US
Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Laboratory Biomarker Analysis, Pomalidomide, 4-Aminothalidomide, Actimid, CC-4047, Imnovid, Pomalyst
Mayo Clinic, National Cancer Institute (NCI)
Plasma Cell Leukemia, Plasma Cell Myeloma, Plasmacytoma
10/20
10/20
NCT04119336: Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma

Terminated
2
2
US
Nivolumab, Opdivo, Ixazomib, Ninlaro, Dexamethasone, Decadron, Cyclophosphamide, Cytoxan
Andrew Yee, MD, Bristol-Myers Squibb, Takeda Pharmaceuticals North America, Inc.
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
11/20
03/22
MUKEight, NCT02461888 / 2014-004511-36: Phase II Randomised Trial of Cyclophosphamide and Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.

Unknown status
2
112
Europe
Ixazomib, Cyclophosphamide, Dexamethasone
University of Leeds, Myeloma UK, Millennium Pharmaceuticals, Inc.
Multiple Myeloma
12/20
01/21
NCT03202628: Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma

Completed
2
8
US
Autologous Hematopoietic Stem Cell Transplantation, autologous stem cell transplantation, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Laboratory Biomarker Analysis, Pomalidomide, 4-Aminothalidomide, Actimid, CC-4047, Imnovid, Pomalyst
Mayo Clinic, National Cancer Institute (NCI)
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
04/21
04/21
IXADES, NCT03213158: Ixazomib for Desensitization

Completed
2
10
US
Ixazomib Oral Capsule
University of Wisconsin, Madison, Millennium Pharmaceuticals, Inc.
Kidney Diseases, End Stage Renal Disease
04/21
04/21
IDEALL, NCT03608501: A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation

Withdrawn
2
0
RoW
Ixazomib, Ixazomib citrate, Thalidomide, Dexamethasone
Takeda
Multiple Myeloma
06/21
05/23
NCT03082677: Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies

Completed
2
20
US
Ixazomib, MLN 9708
Memorial Sloan Kettering Cancer Center, Millennium: The Takeda Oncology Company
Myeloid Hematologic Malignancy, Lymphoid Hematologic Malignancy
09/21
09/21
DARIA, NCT03746652 / 2018-002282-19: Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Unknown status
2
50
Europe
Daratumumab, Ixazomib, Dexamethasone
Hellenic Society of Hematology, Janssen Pharmaceutica NV, Takeda
Multiple Myeloma
12/21
12/21
NCT03439293 / 2017-003977-32: A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Completed
2
61
Europe, US, RoW
Ixazomib, NINLARO, Daratumumab, Dexamethasone
Takeda
Multiple Myeloma
01/22
06/23
NCT02619682: Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Active, not recruiting
2
30
US
Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid
Fred Hutchinson Cancer Center
Plasma Cell Myeloma, Transplant-Related Carcinoma
06/22
10/24
IFM2014-01, NCT03683277: IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic

Terminated
2
26
Europe
Ixazomib/Pomalidomide/Dexamethasone, Multicentric, phase 2, RRMM, refractory, relapse, myeloma
Intergroupe Francophone du Myelome, AXONAL, Nantes University Hospital, University Hospital, Grenoble, Euraxi Pharma, QPS Holdings LLC, Bristol-Myers Squibb, Takeda
Multiple Myeloma, Relapsed and Refractory Multiple Myeloma, Genetic Condition
12/22
02/23
IR regimen as maintainance for high risk MM after ASCT, ChiCTR2000034299: Combination of lenalidomide and ixazomib for maintenance therapy after autologous stem cell transplantation of high-risk multiple myeloma: a prospective, multicenter, single arm phase II study

Recruiting
2
79
 
ixazomib+lenalidomide
Peking University People's Hospital; Peking University People's Hospital, Capital’s Funds for Health Improvement and Research
Multiple Myeloma
 
 
Ixa-Cyto, NCT03965624: Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia

Withdrawn
2
0
Europe
Ninlaro, Ixazomib
Assistance Publique - Hôpitaux de Paris, Takeda Pharmaceuticals International, Inc.
Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia
03/23
09/23
NCT01718743: Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Completed
2
83
US
Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Questionnaire Administration
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma
04/23
04/23
NCT04463953: Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia

Recruiting
2
55
RoW
Zanubrutinib,Ixazomib and Dexamethasone
Institute of Hematology & Blood Diseases Hospital
Waldenström Macroglobulinemia
05/23
05/25
BONE, NCT04028115: Bone Healing During Ninlaro Exposure

Completed
2
30
Europe
Ixazomib, Ninlaro
Thomas Lund
Multiple Myeloma
04/24
04/24
NCT02586038 / 2014-004859-31: STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS

Completed
2
175
Europe
MLN9708, Dexamethasone, Cyclophosphamide, Thalidomide
Mario Boccadoro
Multiple Myeloma
10/23
12/23
NCT03590652: Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma

Active, not recruiting
2
46
US
Ixazomib, Ninlaro, Pomalidomide, Pomalyst, Dexamethasone, Decadron, Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit/15 mL@SUBCUT@VIAL (ML), Darzalex Faspro
University of California, San Diego, Celgene, Takeda, Janssen, LP
Relapsed/Refractory Multiple Myeloma
03/25
10/25
NCT03733691: Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients

Terminated
2
19
US
Ixazomib, Ninlaro, Lenalidomide, Revlimid
Oncotherapeutics, Takeda
Newly Diagnosed Multiple Myeloma
10/23
10/23
NCT03457142: Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy

Active, not recruiting
2
15
US
Abatacept, BMS-188667, CTL A4-Ig B7 Inhibitor, CTLA4-Ig, cytotoxic T lymphocyte-associated antigen-4, Orencia, RG2077, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Laboratory Biomarker Analysis
Roswell Park Cancer Institute, Bristol-Myers Squibb
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
11/22
01/25
NCT02765854: Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement

Active, not recruiting
2
72
US
Dexamethasone, Decadron, DexPak, Dexasone, Baycadron, Zema, Diodex, Hexadrol, Maxidex, Ixazomib, MLN9708, Ninlaro, Ixazomib citrate, Lenalidomide, CC-5013, Revlimid
Emory University, Millennium Pharmaceuticals, Inc., Multiple Myeloma Research Consortium, National Institutes of Health (NIH), National Cancer Institute (NCI)
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
12/23
12/24
NCT03731832: Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma

Active, not recruiting
2
82
Europe
MLN9708, Ixazomib 4.0 mg, Pomalidomide 4 MG Oral Capsule, Dexamethasone, Cyclophosphamide
GWT-TUD GmbH
Refractory Multiple Myeloma
12/23
12/24
NCT02924272 / 2016-001681-28: Ixazomib Rollover Study

Active, not recruiting
2
31
Europe, Canada, Japan, US, RoW
Ixazomib, MLN9708, Ninlaro
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma, Lymphoma, Amyloidosis
02/27
02/27
NCI-2018-01292, NCT03587662: Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Active, not recruiting
2
30
US
Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Gemcitabine Hydrochloride, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Ixazomib, MLN-2238, MLN2238, Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Kidney Medullary Carcinoma, Metastatic Renal Cell Carcinoma, SMARCB1 Negative, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
01/25
01/25
NCT04052880: Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

Recruiting
2
18
US
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Ixazomib
Larysa Sanchez, Janssen, LP
Newly Diagnosed Multiple Myeloma
12/24
06/25
NCT02389517: Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

Active, not recruiting
2
42
US
Ixazomib Citrate, MLN-9708, MLN9708, proteasome inhibitor MLN9708, Lenalidomide, CC-5013, CC5013, CDC 501, IMiD-1, Dexamethasone, DM
University of Chicago, National Cancer Institute (NCI), Multiple Myeloma Research Foundation
Plasma Cell Myeloma, Residual Disease
03/24
03/24
IFM2018-01, NCT03669445: Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma

Recruiting
2
45
Europe
Ixazomib, Lenalidomide, Dexamethasone, Daratumumab
University Hospital, Toulouse
Multiple Myeloma
03/24
12/24
NCT03012880: Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma

Completed
2
80
US
Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Questionnaire Administration
Mayo Clinic, National Cancer Institute (NCI)
Plasma Cell Myeloma
04/22
07/22
NCT03896737 / 2018-002089-37: Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

Active, not recruiting
2
401
Europe, RoW
Daratumumab plus Velcade Cyclophosphamide Dexamethasone, Velcade Thalidomide Dexamethasone
European Myeloma Network, EMN Research Italy
Multiple Myeloma
05/24
02/25
NCT04047797: Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Active, not recruiting
2
24
US
Ixazomib, MLN-2238, MLN2238, Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
06/24
06/24
ChiCTR2000040718: A single arm Trial of Ixazomib plus Thalidomide and dexamethasone as Frontline Therapy in Patients With transplant-ineligible multiple myeloma

Not yet recruiting
2
77
 
ITd for 6 cycles as intinal treatment and IT maintenance therapy for a maximum of 26 cycles(24 months).
Peking University People's Hospital; Peking University People’s Hospital, Takeda (China) International Trading Co.,Ltd
Multiple myeloma
 
 
DeRIVE, NCT03942224: Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Active, not recruiting
2
49
US
Bortezomib, MLN341, PS-341, Velcade, Daratumumab, Anti-cluster of differentiation 38 (CD38) Monoclonal Antibody, Darzalex, HuMax-CD38, Dexamethasone, Decadron, Dexasone, Diodex, Hexadrol, Maxidex, Ixazomib, Ninlaro, MLN2238
Emory University, Takeda, Janssen, LP, National Institutes of Health (NIH), National Cancer Institute (NCI)
Plasma Cell Myeloma
07/25
07/26
IPoD-790, NCT04790474: Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib

Recruiting
2
60
RoW
ixazomib-pomalidomide-dexamethasone
Tel-Aviv Sourasky Medical Center
Multiple Myeloma in Relapse, Refractory Multiple Myeloma
09/24
10/24
ChiCTR2200066532: A single-center, single-arm, open-label, phase II clinical study of chidamide combined with ixazomib, cyclophosphamide, and dexamethasone (ICD) in the treatment of relapsed and refractory multiple myeloma

Not yet recruiting
2
80
 
chidamide combined with ixazomib, cyclophosphamide, and dexamethasone
Union Hospital Fujian Medical University; Union Hospital Fujian Medical University, enterprise cooperation
multiple myeloma
 
 
NCI-2018-02830, NCT03763162: Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Active, not recruiting
2
40
US
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Ixazomib, MLN-2238, MLN2238, Quality-of-Life Assessment, Quality of Life Assessment
M.D. Anderson Cancer Center, Takeda
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
12/24
12/24
IDARA, NCT03757221 / 2018-001646-34: Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma

Recruiting
2
70
Europe
Ixazomib and Daratumumab
University Hospital, Caen
Multiple Myeloma
12/24
12/25
I2D IFM2021_03, NCT04998786: A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."

Active, not recruiting
2
80
Europe
Ixazomib, Iberdomide, Dexamethasone Oral
Nantes University Hospital
Multiple Myeloma at First Relapse
01/25
01/27
NCT02339922: Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

Active, not recruiting
2
33
US
Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Laboratory Biomarker Analysis, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83, Rituximab Biosimilar SIBP-02
University of Washington, Millennium Pharmaceuticals, Inc.
Chronic Lymphocytic Leukemia, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia
01/25
01/31
NCT04837131: A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients

Terminated
2
3
US
Ixazomib
Michael M. Pham
Systemic Sclerosis, Scleroderma, Diffuse Systemic Sclerosis, Diffuse Scleroderma, Diffuse Cutaneous Systemic Sclerosis, Diffuse Cutaneous Scleroderma, Progressive Systemic Sclerosis, Progressive Scleroderma, Scleroderma, Systemic, Scleroderma, Diffuse, Scleroderma;Progressive, Systemic Sclerosis, Diffuse, Systemic; Sclerosis, Progressive, Scleroderma of Lung, Scleroderma With Pulmonary Involvement, Systemic Sclerosis Pulmonary, Systemic Sclerosis With Lung Involvement, Interstitial Lung Disease, Pulmonary Fibrosis Interstitial
02/24
02/24
NCT02916771: Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

Active, not recruiting
2
55
US
Ixazomib, Ninlaro, Lenalidomide, Revlimid, Dexamethasone, Decadron
Dana-Farber Cancer Institute, Celgene, Takeda
Smoldering Multiple Myeloma
04/25
04/25
NCT03506373: Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

Active, not recruiting
2
23
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Laboratory Biomarker Analysis, Pharmacodynamic Study, PHARMACODYNAMIC, Pharmacokinetic Study, PHARMACOKINETIC, PK Study
Mayo Clinic, National Cancer Institute (NCI)
Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia, Waldenstrom Macroglobulinemia
05/25
05/25
NCT04305691: Trial of Ixazomib for Kaposi Sarcoma

Recruiting
2
41
US
Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
AIDS Malignancy Consortium, National Cancer Institute (NCI)
Kaposi Sarcoma, Skin
05/25
05/26
NCT04009109: Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

Active, not recruiting
2
79
US
Lenalidomide, Revlimid, Ixazomib, Ninlaro, Daratumumab Injection, Darzalex, Dexamethasone, Ozurdex
Alliance Foundation Trials, LLC., Janssen Scientific Affairs, LLC, Celgene Corporation, Takeda
Myeloma, Multiple
10/25
07/26
NCT01415882: Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib

Active, not recruiting
2
165
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Laboratory Biomarker Analysis
Mayo Clinic, National Cancer Institute (NCI)
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
04/23
02/26
NCT03616782: Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)

Recruiting
2
98
RoW
Ixazomib
Ho Sup Lee, Takeda
Mantle Cell Lymphoma
05/26
05/26
NCT03618537: Ixazomib Maintenance Study in Patients With AL Amyloidosis

Active, not recruiting
2
17
US
Ixazomib, Dexamethasone
Memorial Sloan Kettering Cancer Center, Tufts Medical Center, Vanderbilt University Medical Center
AL Amyloidosis
08/26
08/26
NCT03376672: Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients

Active, not recruiting
2
120
Europe
Ixazomib, Lenalidomide, Dexamethasone
Raija Silvennoinen, Nordic Myeloma Study Group, Celgene, Takeda
Multiple Myeloma
12/27
12/27
NCT01217957: A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Checkmark In combination with lenalidomide and pomalidomide in RRMM: ASH 2015
Dec 2015 - Dec 2015: In combination with lenalidomide and pomalidomide in RRMM: ASH 2015
Checkmark P1/2 data EHA 2012
May 2012 - May 2012: P1/2 data EHA 2012
Checkmark P1/2 data at ASH 2011
More
Completed
1/2
65
US
Ixazomib, MLN9708, NINLARO®, Lenalidomide, Dexamethasone
Millennium Pharmaceuticals, Inc.
Multiple Myeloma
03/13
02/18
2013-002711-94: HOVON 124 WM study: A trial of the combination of ixazomib citrate, rituximab and dexamethasone in patients with relapsed or progressive Waldenström's macroglobulinemia.

Ongoing
1/2
72
Europe
MLN9708 4 mg, rituximab, MLN9708 3 mg, MLN9708 2,3 mg, Capsule, hard, Concentrate for solution for infusion, Solution for injection, Mabthera 100mg/10ml, Mabthera 500mg/50ml, Mabthera s.c.
HOVON Foundation, Dutch Cancer Society, Millennium, Roche Nederland BV, Roche Belgium, Roche (Hellas) S.A.
Waldenström's macroglobulinemia, Morbus Waldenström, Diseases [C] - Cancer [C04]
 
 
NCT01383928: Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma

Checkmark MLN9708+Lenalidomide+Dexamethasone in newly diagnosed MM pts
Dec 2013 - Dec 2013: MLN9708+Lenalidomide+Dexamethasone in newly diagnosed MM pts
Checkmark ASH 2013
Nov 2013 - Nov 2013: ASH 2013
Checkmark P1/2 data-ASCO
More
Completed
1/2
64
US
Ixazomib, Lenalidomide, Dexamethasone
Millennium Pharmaceuticals, Inc.
Multiple Myeloma
10/14
11/17
NCT02119468: Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Completed
1/2
32
US
ixazomib citrate, MLN9708, proteasome inhibitor MLN9708, dexamethasone, Aeroseb-Dex, Decaderm, Decadron, DM, DXM, pomalidomide, CC-4047, Pomalyst
City of Hope Medical Center, National Cancer Institute (NCI)
Refractory Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma
05/16
12/22
NCT01335685 / 2010-023772-71: Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma

Checkmark P1 data EHA 2012
May 2012 - May 2012: P1 data EHA 2012
Completed
1/2
61
US, Canada, Europe, RoW
Ixazomib, Melphalan, Prednisone
Millennium Pharmaceuticals, Inc.
Multiple Myeloma
12/16
12/16
NCT02447887: Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)

Terminated
1/2
3
US
Ixazomib, Pegylated IFN-alpha 2b, pIFN - alpha 2b
Fox Chase Cancer Center
Metastatic Renal Cell Carcinoma, RCC
04/17
04/17
NCT02206425: Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Completed
1/2
45
US
Melphalan, Phenylalanine mustard, Alkeran, Prednisone, Cortan, Deltasone, Orasone, Prednisone Intensol, Sterapred, Sterapred DS, Cyclophosphamide, Cytoxan, CPM, CTX, CYT, Dexamethasone, Decadron, Dexamethasone Intensol, Dexpak Taperpak, Ascorbic acid, Vitamin C, PLD, ATI-0918, doxorubicin hydrochloride liposome, doxorubicin hydrochloride liposome injection, liposomal adriamycin, liposomal doxorubicin, liposomal doxorubicin hydrochloride, liposome-encapsulated doxorubicin, pegylated doxorubicin HCl liposome, Pegylated Liposomal Doxorubicin, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, DOXIL, Dox-SL, Evacet, LipoDox, Lenalidomide, Revlimid, Pomalidomide, Pomalyst
Oncotherapeutics, Takeda
Multiple Myeloma
01/18
03/18
NCT02477215: Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma

Completed
1/2
38
US
MLN9708, Ixazomib, Dexamethasone, Decadron, Bendamustine (multiple dose levels), Treanda, Treakisym, Ribomustin, Bendamustine (MTD)
Parameswaran Hari
Multiple Myeloma
05/18
09/20
NCT02057640: MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma

Completed
1/2
16
US
Panobinostat, Dexamethasone, MLN9708, Ixazomib
Jason Valent
Multiple Myeloma, Kahler Disease, Plasma-Cell Myeloma, Myelomatosis
05/18
05/18
NCT02898259: Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma

Terminated
1/2
19
US
Ixazomib, Lenalidomide, Revlimid, Rituximab, Rituxan
Brian Hill, The Cleveland Clinic
B Cell Lymphoma, Lymphoma
10/18
06/22
NCT02946047: The Effect of Ixazomib on the Latent HIV Reservoir

Completed
1/2
17
US
Ixazomib 1 MG, Ninlaro, Ixazomib 2 MG, Ixazomib 3 MG, Ixazomib 4 MG
Mayo Clinic, Takeda
Human Immunodeficiency Virus (HIV)
08/19
08/19
NCT03492138: Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Terminated
1/2
5
US
ONC201, Ixazomib, Dexamethasone
Ajai Chari
Multiple Myeloma
01/20
01/20
NCT02993094 / 2016-001421-13: Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer

Terminated
1/2
31
Europe
Ixazomib, MLN9708, Carboplatin
Arbeitsgemeinschaft medikamentoese Tumortherapie, Takeda
Triple-Negative Breast Cancer
08/20
08/20
NCT02481310: Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

Active, not recruiting
1/2
38
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, Ixazomib Citrate, MLN-9708, MLN9708, Laboratory Biomarker Analysis, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisonum, Prednitone, Promifen, Servisone, SK-Prednisone, Rituximab, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar BI 695500, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, RTXM83, Therapeutic Hydrocortisone, Aeroseb-HC, Barseb HC, Barseb-HC, Cetacort, Cort-Dome, Cortef, Cortenema, Cortifan, Cortisol, Cortispray, Cortril, Dermacort, Domolene, Eldecort, Hautosone, Heb-Cort, HYDROCORTISONE, Hydrocortone, Hytone, Komed-HC, Nutracort, Proctocort, Rectoid, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Northwestern University, National Cancer Institute (NCI), Millennium Pharmaceuticals, Inc.
Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, MYC Gene Mutation, Plasmablastic Lymphoma
09/20
07/24
NCT02250300: MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation

Completed
1/2
68
US
MLN9708 (2.3 mg), Ixazomib, MLN9708 (4.0 mg), MLN9708 (3.0 mg)
Mehdi Hamadani
Allogeneic Hematopoietic Stem Cell Transplantation
10/20
10/20
NCT02633059: Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Active, not recruiting
1/2
33
US
Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Idasanutlin, RG-7388, RG7388, RO-5503781, RO5503781, Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Laboratory Biomarker Analysis, Pharmacological Study
Mayo Clinic, National Cancer Institute (NCI)
Loss of Chromosome 17p, Recurrent Plasma Cell Myeloma
01/21
12/24
NCT03547700: Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

Active, not recruiting
1/2
11
US
Romidepsin, Istodax, Ixazomib, Ninlaro
Ryan Wilcox, University of Michigan Rogel Cancer Center, Takeda
Lymphoma, T-Cell, Peripheral
03/21
07/21
MC1382, NCT01864018: Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Active, not recruiting
1/2
87
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Mayo Clinic, National Cancer Institute (NCI)
Amyloidosis, Plasma Cell Myeloma
04/21
10/24
NCT04079738: Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib

Terminated
1/2
8
US
TAK-659, Ixazomib
H Scott Boswell, Takeda
AML, AML, Adult
09/21
02/22
A061202, NCT02004275: Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma

Active, not recruiting
1/2
118
US
pomalidomide, Pomalyst®, ixazomib, MLN9708, dexamethasone
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Celgene Corporation, Millennium Pharmaceuticals, Inc.
Multiple Myeloma in Relapse
12/21
 
NCT03856112: Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma

Withdrawn
1/2
0
NA
Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Ixazomib, MLN-2238, MLN2238, Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta
National Cancer Institute (NCI)
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, t(11;14) Negative
12/21
12/21
MyDRUG, NCT03732703: Myeloma-Developing Regimens Using Genomics

Checkmark Data from MyDRUG study for MM at ASH 2022
Dec 2022 - Dec 2022: Data from MyDRUG study for MM at ASH 2022
Recruiting
1/2
228
US
Abemaciclib, dexamethasone, ixazomib, pomalidomide, abemaciclib: Verzenio, LY2835219, ixazomib: Ninlaro, MLN2238, pomalidomide: Pomalyst, Enasidenib, dexamethasone, ixazomib, pomalidomide, enasidenib: AG221, IDHIFA, Cobimetinib, dexamethasone, ixazomib, pomalidomide, cobimetinib: Cotellic, GDC-0973, RG7420, Erdafitinib, dexamethasone, ixazomib, pomalidomide, erdafitinib: G-024, JNJ-42756493, JNJ-493, Venetoclax, dexamethasone, ixazomib, pomalidomide, venetoclax: Venclexta: ABT-199, Daratumumab, dexamethasone, ixazomib, pomalidomide, daratumumab: Darzalex, Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide, Belantamab mafodotin: BLENREP, GSK2857916, Selinexor, dexamethasone, ixazomib, pomalidomide, Selinexor: XPOVIO
Multiple Myeloma Research Consortium, AbbVie, Celgene Corporation, Eli Lilly and Company, Genentech, Inc., Janssen, LP, Takeda, GlaxoSmithKline, Karyopharm Therapeutics Inc
Relapsed Refractory Multiple Myeloma
02/22
02/24
NCT03236792: Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis

Completed
1/2
28
US
Ixazomib, Cyclophosphamide, Dexamethasone
Icahn School of Medicine at Mount Sinai, Millennium Pharmaceuticals, Inc.
AL Amyloidosis
09/22
09/22
 

Download Options